Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.

Mei Kim AngJose Enrique MontoyaEkkasit TharavichitkulCindy LimTerence TanLan Ying WangJoseph WeeYoke-Lim SoongKam-Weng FongQuan Sing NgDaniel Shao-Weng TanChee-Keong TohEng-Huat TanWan-Teck Lim

Published in: Head & neck (2021)

The combination of nimotuzumab with cisplatin and radiotherapy was safe and achieved high response rates in HNSCC.

Keyphrases

locally advanced
phase ii study
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
early stage
randomized controlled trial
radiation induced
clinical trial
study protocol